Advertisements

Diaprel MR

Quick links to important sections

Diaprel MR

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Diaprel MR

What is Diaprel MR?

Diaprel MR is an oral medication used to help manage blood sugar levels in adults with type 2 diabetes. It belongs to a group of medicines known as sulfonylureas.

The active substance in Diaprel MR is gliclazide. The "MR" in its name stands for modified release, which means the medication is designed to release the active ingredient gradually into the bloodstream over a 24-hour period. This delivery method allows for a consistent effect on blood glucose throughout the day.

How it Works

Diaprel MR works primarily by stimulating the pancreas to produce more insulin. Insulin is the hormone responsible for moving glucose from the bloodstream into the body's cells, where it is used for energy. By increasing insulin secretion, the medication helps to lower elevated blood sugar levels that occur in type 2 diabetes.

In addition to stimulating insulin release, gliclazide may also improve the body’s sensitivity to the insulin it produces. It is typically used when dietary changes, physical exercise, and weight loss alone are not sufficient to maintain healthy blood glucose levels. While it helps control blood sugar, it is intended to be used as part of a comprehensive management plan that includes lifestyle modifications.

Advertisements

What side effects are possible with Diaprel MR?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety constraints for Diaprel MR (Gliclazide Modified Release), based strictly on government regulatory documents such as the Summary of Product Characteristics (SmPC).


Official Adverse Reactions by Frequency

The most frequent documented adverse reaction is hypoglycaemia (low blood sugar), which is officially categorized as Common (occurring in 1/100 to < 1/10 patients). Other effects are classified as Uncommon or Rare.

Frequency Category System-Organ Class Key Adverse Reactions
Common Metabolism and Nutrition Hypoglycaemia
Uncommon Gastrointestinal Disorders Abdominal pain, Nausea, Vomiting, Constipation, Diarrhoea
Rare/Not Known Blood and Lymphatic System Anaemia, Thrombocytopenia (low platelets)
Not Known Hepatobiliary Disorders Hepatitis, Cholestatic Jaundice
Not Known Skin and Subcutaneous Tissue Rash, Angioedema, Bullous Reactions (e.g., SJS, TEN)

Serious Safety Considerations

Serious Adverse Reactions documented in regulatory labeling include severe forms of hypoglycaemia (potentially leading to coma), Hepatitis, and severe Bullous Skin Reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Population-Specific Constraints

Diaprel MR is generally contraindicated in individuals with severe renal or hepatic failure, as hypoglycaemic episodes may be prolonged. Use is also contraindicated during pregnancy and lactation, and is not recommended for children and adolescents.

Exposure-Related Safety Notes

The label notes that transient visual disturbances may occur upon initiation of treatment due to fluctuations in blood glucose. Gastrointestinal effects can be minimized when the medication is taken with breakfast.

Advertisements

Overdose and Emergency Response

The signs of Diaprel MR overdose are documented as those of severe and/or prolonged hypoglycaemia (low blood sugar), which constitutes the primary documented overdose state. The clinical manifestations of low blood sugar span a spectrum of autonomic and neurological signs. Initial symptoms may include headache, intense hunger, nausea, weariness, and disorientation. Autonomic signs often involve profuse sweating, clammy skin, restlessness, anxiety, and a fast or irregular heart beat (tachycardia).

If an overdose is suspected, or if too many tablets have been taken, immediate medical attention is required. The official regulatory instruction is to contact a doctor or the nearest hospital Accident & Emergency department immediately. Severe symptoms indicate a medical emergency. If the patient is unconscious, emergency services must be called immediately. Severe and prolonged hypoglycaemia can progress to convulsions or coma, carrying the risk of permanent impairment of brain function or death.

For conscious patients, immediate action involves consuming carbohydrates (sugar). For severe cases, management necessitates hospitalisation for correction with intravenous glucose administration. Extended monitoring may be required, as the glucose treatment may need to be continued for several days. Specific considerations exist for those with renal or severe hepatic insufficiency, who are noted to be at an increased risk of prolonged hypoglycaemia.

Advertisements

Therapeutic Uses of Diaprel MR

Diaprel MR (Gliclazide Modified Release) is a prescription treatment option used for the management of Type 2 Diabetes Mellitus in adults. Its primary use is in individuals whose blood sugar levels require support beyond lifestyle changes, such as a controlled diet and regular physical activity.

This medication is approved to assist in improving overall glycemic control by helping to lower elevated blood glucose levels. Effectively managing these high blood sugar levels (hyperglycemia) is essential for supporting patient well-being and is a core part of long-term diabetes care. The clinical scenarios for its use include monotherapy and combination therapy with other anti-diabetic agents, as determined by a healthcare provider.

Diaprel MR is intended to support the management of key glucose metrics, specifically high fasting glucose and postprandial (after-meal) glucose.

Quick Fact: Relief for High Blood Glucose
Diaprel MR is a treatment intended to help maintain appropriate blood sugar levels as part of a comprehensive care plan.
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Diaprel MR?

The official regulatory profile for Diaprel MR (Gliclazide Modified Release) defines specific population rules for its use, based strictly on governmental documents.

Category Eligibility Status Restriction Severity
Approved Population Adults with Type 2 Diabetes Mellitus Standard Use
Children/Adolescents Safety and effectiveness not established Not Recommended
Older Adults (≥65 years) Use is Established No Dosage Adjustment Required

Absolute Contraindications (Must Not Be Used)

Diaprel MR is formally contraindicated (prohibited) in several patient groups, including those with:

  • Type 1 Diabetes Mellitus or acute complications such as diabetic keto-acidosis or diabetic pre-coma.
  • Severe Renal Insufficiency (severe kidney disease) or Severe Hepatic Insufficiency (severe liver disease), where insulin use is generally recommended.
  • Known Hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamide-derived drugs.
  • Concomitant treatment with the antifungal medication Miconazole (systemic or oromucosal gel).
  • Pregnancy or Lactation (breastfeeding).

Eligibility-Related Restrictions

The medicine is not recommended for use in children or adolescents, as its safety and effectiveness have not been established in this age group. Additionally, for patients facing Stress Conditions (such as trauma or surgery), the medication may need to be discontinued and insulin administered, as advised in regulatory labeling.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Diaprel MR (Gliclazide) is defined by its core therapeutic action, detailing substances that officially modify its blood glucose-lowering effect. Miconazole (systemic or oromucosal gel) is a formally contraindicated combination due to the risk of severe, potentiated hypoglycemia. Similarly, Alcohol and alcohol-containing medicines must be avoided as they increase the hypoglycemic reaction by inhibiting the body's compensatory responses.

Many medicinal products are documented to influence Gliclazide's activity. Combinations that increase the risk of hypoglycemia include other antidiabetic agents, Beta-blockers, ACE Inhibitors, and Fluconazole. The nonsteroidal anti-inflammatory agent Phenylbutazone is specifically noted to increase Gliclazide exposure by reducing its elimination and causing plasma protein binding displacement. Conversely, substances such as Danazol, high-dose Chlorpromazine, and Rifampicin are documented to reduce the efficacy of Gliclazide, leading to a risk of hyperglycemia.

Official labeling requires a treatment-free period of a few days when switching from a sulfonylurea with a long half-life to prevent an additive effect. Furthermore, the risk of blood glucose disturbances (dysglycemia) is heightened when Fluoroquinolones are co-administered, particularly in elderly patients. For those with hepatic or severe renal impairment, the altered pharmacokinetics and/or pharmacodynamics may result in a prolonged hypoglycemic episode.

Advertisements

Mechanism of Action

️ K ATP Channel Blockade and beta-Cell Activation

The primary mechanism of Gliclazide involves binding to the Sulfonylurea Receptor 1 ( SUR1), a regulatory subunit of the K ATP channel complex on pancreatic beta-cells. This interaction functionally blocks the channel, halting the efflux of potassium ions ( K^+) and initiating the electrical depolarization of the cell membrane.

Calcium Influx Cascade and Insulin Secretion

Membrane depolarization opens voltage-gated Calcium ( Ca^2+) channels, leading to a rapid influx of calcium ions into the cell. This surge in intracellular Ca^2+ concentration is the final signal that drives the exocytosis (release) of stored insulin vesicles into the circulation. This action results in enhanced and accelerated secretion of the body's own natural insulin, specifically modulating the first-phase insulin response to rising glucose levels.

️ Secondary Antioxidant Effect

Beyond its direct secretagogue activity, Gliclazide also possesses inherent antioxidant properties. This secondary mechanism is associated with a reduction in harmful oxidative stress within the insulin-producing beta-cells, an action that may support the maintenance of beta-cell viability.

Advertisements

Dosage and Administration Information

Official Administration of Diaprel MR

The medication is administered exclusively via the oral route as a modified-release tablet, which dictates specific rules for its daily use and physical handling. The dosing regimen is standardized for long-term management.


Administration Schedule and Dosage

Instruction Area Guideline
Route of Administration Oral intake only.
Dosing Frequency Once daily, taken in a single intake.
Timing in Relation to Meals Must be taken at breakfast time as part of a regular food intake.
Starting Dose 30 mg daily.
Maximum Daily Dose 120 mg daily.

Procedural Use and Titration

The tablet(s) must be swallowed whole with water and should not be crushed or chewed in order to maintain the modified-release properties. This specific administration method ensures the drug's intended continuous release.

Dose adjustment, or titration, is performed based on the patient's metabolic response. Increments in the daily dose should occur in steps of 30 mg at intervals of at least one month. If blood glucose is not adequately controlled, the dose may be increased after a shorter interval of two weeks.

For older adults (≥ 65 years) and patients with mild-to-moderate renal impairment, the 30 mg starting dose and careful monitoring are generally recommended. If a dose is forgotten, it must be skipped, and the subsequent day’s dose should not be increased to compensate.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Mechanism of Action and Basis for Study

The clinical trials were conducted based on preclinical research investigating the drug's interaction with pancreatic beta cells, which helps manage blood glucose. The drug's classification in the trials was as an oral anti-diabetic agent, specifically a sulfonylurea.


ADVANCE Trial Findings

The Action in Diabetes and Vascular Disease: PreterAx and DiamicroN MR Controlled Evaluation (ADVANCE) trial was a large-scale, randomized, controlled study. It reported on the effects of a gliclazide MR-based intensive glucose control strategy (using Diaprel MR) compared to a standard control group in patients with type 2 diabetes.

  • Study Population: The trial included over 11,000 patients with type 2 diabetes and a high cardiovascular risk profile.
  • Primary Outcome: The trial reported a significant finding regarding the composite of major macrovascular and microvascular events.

Effects on Microvascular Events

Secondary findings from the ADVANCE trial and subsequent meta-analyses examined specific outcomes.

Outcome Reported Difference vs. Standard Control
New or Worsening Nephropathy Reported a relative reduction in incidence
Retinopathy No significant difference observed

Safety and Tolerability

Safety data collected during the study reported on adverse events.

  • Hypoglycemia: The most common adverse event reported was severe hypoglycemia, which occurred more frequently in the intensive control group compared to the standard control group.
  • Body Weight: The intensive control group was also associated with a greater increase in body weight during the study period.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Diaprel MR (FAQ)


Q: Is Diaprel MR the same type of drug as metformin?

A: According to the official product information, Diaprel MR, which contains Gliclazide, is classified as a sulfonylurea class drug, which is an insulin secretagogue. This classification describes its action of stimulating the pancreas to release insulin. This is a different pharmacological class from biguanide drugs, such as metformin.


Q: Can Diaprel MR cause weight gain?

A: Studies and official information indicate that the intensive blood sugar control strategy using Gliclazide MR, such as in the ADVANCE trial, was associated with a greater increase in body weight during the study period compared to a standard control group.


Q: Can I take Diaprel MR if I have kidney issues?

A: Regulatory documents state the medication is contraindicated (must not be used) in cases of severe renal insufficiency (severe kidney disease). For patients with mild-to-moderate renal impairment, a lower starting dose and careful medical monitoring are generally described to support appropriate management of the drug.


Q: Does Diaprel MR interact with common blood pressure medications?

A: Official labeling states that combining Diaprel MR with certain types of common blood pressure medications, specifically Beta-blockers and ACE Inhibitors, is documented to increase the risk of hypoglycemia (low blood sugar).


Q: Is Diaprel MR known to interact with alcohol?

A: Regulatory documents advise that alcohol and alcohol-containing medicines must be avoided while taking Diaprel MR. This is because alcohol can increase the hypoglycemic reaction by inhibiting the body's compensatory responses.


Q: What if I take too much Diaprel MR by mistake?

A: Taking too much of this medication or other sulfonylureas is documented to potentially lead to severe hypoglycaemia (very low blood sugar). If an overdose is suspected, official guidance states that immediate medical attention and professional treatment are necessary as documented in official labeling.


Q: What are the key points official sources make about starting Diaprel MR?

A: Key points described in official documents include taking the tablet whole once a day at breakfast time with food. Official documents emphasize the importance of maintaining a regular food intake because of the risk of hypoglycemia. The medication is always initiated at the lowest effective dose.


Q: What is Diaprel MR used for besides controlling blood sugar?

A: The officially approved therapeutic indication for the medication is exclusively for the treatment of Type 2 Diabetes Mellitus in adults. Its purpose is to achieve effective glycemic control (blood sugar control) as a supportive measure to diet and exercise.


Q: What are the most common side effects of Diaprel MR that people report?

A: According to official adverse reaction tables, the most frequent documented side effect is hypoglycaemia (low blood sugar). This effect is officially categorized as Common, meaning it occurs in at least 1 in 100 patients.


Q: Is it common to feel dizzy or light-headed when taking Diaprel MR?

A: Dizziness and light-headedness are not listed as stand-alone common side effects. However, they are described in regulatory documents as possible signs or symptoms of hypoglycaemia (low blood sugar), which is the most frequent documented adverse reaction.


Q: What happens if I forget to take my Diaprel MR dose?

A: Official guidance states that if a dose is forgotten, it must be skipped entirely. The subsequent day's dose should not be increased to compensate for the missed dose, as this increases the risk of hypoglycemia.


Q: Are there any specific foods I should avoid while on Diaprel MR?

A: While no specific foods are forbidden, official labeling strongly emphasizes the importance of maintaining a regular food intake, including breakfast. This regular timing is emphasized because skipping or delaying a meal increases the risk of hypoglycemia. Alcohol is specifically advised to be avoided.


Q: Do older adults typically need a different dose of Diaprel MR?

A: For older adults (aged 65 years and over), official documents state that no specific dosage adjustment is required compared to younger adults. However, a low starting dose and careful monitoring are generally recommended.


Q: Is it possible to develop a tolerance to Diaprel MR over time?

A: Regulatory documents note that the effectiveness of oral antidiabetic agents may decrease in the long term, a phenomenon described as secondary failure. This is related to the natural progression of diabetes or a reduced overall response to treatment over time.


Q: How does Diaprel MR affect other diabetes medications?

A: Official documentation indicates that combination with other antidiabetic agents may result in an increased blood glucose-lowering effect. This combination poses an increased risk of hypoglycaemia (low blood sugar).


Q: Does Diaprel MR cause frequent urination?

A: Frequent urination is not listed as a direct side effect of the medication itself. However, official documents describe it as a possible symptom of hyperglycaemia (high blood sugar) that may occur if the drug has not sufficiently controlled blood sugar levels.


Q: Are there alternative names for Diaprel MR I might see in other countries?

A: The active ingredient in Diaprel MR is Gliclazide. Due to different pharmaceutical company names, other brand names for medications containing Gliclazide may exist in various countries.


Q: What does research evidence say about long-term use of Diaprel MR?

A: Research evidence includes findings from the large-scale ADVANCE trial, which reported on the effects of a Gliclazide MR-based strategy over an extended period. The study examined the effects on major macrovascular and microvascular events in patients with type 2 diabetes.


Q: Can taking Diaprel MR affect my ability to drive or operate machinery?

A: Official documents caution that the medication may cause drowsiness or dizziness, which could affect the ability to drive or operate machinery. This risk is particularly noted as a symptom of low blood sugar.


Q: Are headaches a commonly reported side effect of Diaprel MR?

A: Headaches are not listed as a standalone common side effect. However, regulatory documents state that a headache is a possible symptom of hypoglycaemia (low blood sugar), which is the most frequent documented adverse reaction of the drug.


Q: Can people with lactose intolerance take Diaprel MR?

A: Official information notes that the medication contains lactose monohydrate as an inactive component, or excipient. The presence of this excipient is noted in the official product information.


Q: What are the signs that Diaprel MR is working as intended?

A: The intended effect of the medication is to provide effective glycemic control (improved blood sugar management). Official guidance describes dose adjustment based on an individual patient's metabolic response, which includes measures of blood glucose and HbA1c.


Q: What should I know about taking Diaprel MR before a surgery?

A: Official labeling advises that during stress-situations such as trauma, fever, or surgical operations, the medication may need to be temporarily discontinued and replaced with insulin therapy.


Q: Can the effectiveness of Diaprel MR be impacted by stress or illness?

A: Regulatory documents note that stress-situations (e.g., accidents, fever, or surgical operations) may lead to a loss of blood sugar control. Such situations could require a temporary change in treatment, such as switching to insulin.

Advertisements

How should Diaprel MR be stored and disposed of?

How to Store and Dispose of Diaprel MR?

The storage and disposal of Diaprel MR (gliclazide modified-release) must strictly adhere to official regulatory requirements to ensure product integrity and public safety.

Official Storage Requirements

Storage Component Requirement as Stated in Official Labeling
Temperature No special storage conditions are required.
Container Rule Store the tablets in the original container (blister pack).
Safety Must be kept out of the sight and reach of children.

The official labeling clarifies that no specific refrigeration or freezing instructions are necessary. The tablets are stable when maintained in the original, protective packaging.

Disposal Mandates

Unused or expired Diaprel MR must not be disposed of via wastewater or household waste (trash). Disposal must follow local requirements for pharmaceutical waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diaprel MR found in:

A-Z Index: